QIAGEN Expands Alliance with Protedyne Corporation
Investment of approximately US$ 2.0 million
Advertisement
QIAGEN N.V. and Protedyne Corporation announced that they have expanded their strategic alliance to jointly market and cross-promote the use of Protedyne's BioCube System in conjunction with QIAGEN's QIAamp nucleic acid purification products as an integrated fully automated ultra-high throughput sample preparation system for high throughput research and molecular diagnostics markets.
In addition, QIAGEN will invest approximately US$ 2.0 million in Protedyne. QIAGEN has been granted exclusive access to Protedyne's high throughput automation platform technologies for filter-based nucleic acid sample preparation. This strategic alliance is the result of a successful collaboration announced in June 2004. The first commercial system will be available during Q2 of 2005.